Targeted delivery of curcumin for treating type 2 diabetes

Molecular Nutrition and Food Research

Volumn 57, Issue 9, 2013, Pages 1550-1556

  Maradana, Muralidhara Rao ^a   Thomas, Ranjeny ^a   O'Sullivan, Brendan J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Curcumin; Liposomes; Macrophages; NF B; Type 2 diabetes

Indexed keywords

CURCUMA LONGA;

CURCUMIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LIPOSOME; NANOPARTICLE; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA;

ADIPOSE TISSUE; ANIMAL; BLOOD; CHEMISTRY; CURCUMA; DISEASE MODEL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIVER; LIVER DISEASE; MACROPHAGE; METABOLISM; METHODOLOGY; NF-ΚB; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

CURCUMIN; LIPOSOMES; MACROPHAGES; NF-ΚB; TYPE 2 DIABETES;

ADIPOSE TISSUE; ANIMALS; CURCUMA; CURCUMIN; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; I-KAPPA B PROTEINS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LIVER; LIVER DISEASES; NANOPARTICLES; NF-KAPPA B; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84883456347     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201200791     Document Type: Review

References (63)

1. Donath, M. Y., Shoelson, S. E., Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 2011, 11, 98-107.
2. Piccinini, A. M., Midwood, K. S., DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010, doi: 10.1155/2010/672395.
3. Kawai, T., Akira, S., The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat. Immunol. 2010, 11, 373-384.
4. Shoelson, S. E., Lee, J., Goldfine, A. B., Inflammation and insulin resistance. J. Clin. Invest. 2006, 116, 1793-1801.
5. Evans, J. L., Goldfine, I. D., Maddux, B. A., Grodsky, G. M., Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 2002, 23, 599-622.
6. Osborn, O., Olefsky, J. M., The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 2012, 18, 363-374.
7. Rumore, M. M., Kim, K. S., Potential role of salicylates in type 2 diabetes. Ann. Pharmacother. 2010, 44, 1207-1221.
8. Olefsky, J. M., Glass, C. K., Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010, 72, 219-246.
9. Doshi, L. S., Brahma, M. K., Bahirat, U. A., Dixit, A. V. et al., Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents. Expert Opin. Investig. Drugs 2010, 19, 489-512.
10. Hevener, A. L., Olefsky, J. M., Reichart, D., Nguyen, M. T. et al., Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 2007, 117, 1658-1669.
11. Patsouris, D., Li, P. P., Thapar, D., Chapman, J. et al., Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 2008, 8, 301-309.
12. Deng, Z. B., Liu, Y. L., Liu, C. R., Xiang, X. Y. et al., Immature myeloid cells induced by a high-fat diet contribute to liver inflammation. Hepatology 2009, 50, 1412-1420.
13. Obstfeld, A. E., Sugaru, E., Thearle, M., Francisco, A. M. et al., C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes 2010, 59, 916-925.
14. Weisberg, S. P., Hunter, D., Huber, R., Lemieux, J. et al., CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 2006, 116, 115-124.
15. Arkan, M. C., Hevener, A. L., Greten, F. R., Maeda, S. et al., IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 2005, 11, 191-198.
16. Yin, M. J., Yamamoto, Y., Gaynor, R. B., The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396, 77-80.
17. Van Dommelen, S. L. H., Degli-Esposti, M. A., NKT cells and viral immunity. Immunol. Cell Biol. 2004, 82, 332-341.
18. Falcone, M., Facciotti, F., Ghidoli, N., Monti, P. et al., Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice. J. Immunol. 2004, 172, 5908-5916.
19. Jiang, X., Kojo, S., Harada, M., Ohkohchi, N. et al., Mechanism of NKT cell-mediated transplant tolerance. Am. J. Transplant. 2007, 7, 1482-1490.
20. Elinav, E., Pappo, O., Sklair-Levy, M., Margalit, M. et al., Adoptive transfer of regulatory NKT lymphocytes ameliorates non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice and is associated with intrahepatic CD8 trapping. J. Pathol. 2006, 209, 121-128.
21. Kremer, M., Thomas, E., Milton, R. J., Perry, A. W. et al., Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology 2010, 51, 130-141.
22. Nishimura, S., Manabe, I., Nagasaki, M., Eto, K. et al., CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 2009, 15, 914-920.
23. Winer, S., Chan, Y., Paltser, G., Truong, D. et al., Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 2009, 15, 921-929.
24. Winer, D. A., Winer, S., Shen, L., Wadia, P. P. et al., B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 2011, 17, 610-617.
25. Nikolajczyk, B. S., Jagannathan-Bogdan, M., Shin, H., Gyurko, R., State of the union between metabolism and the immune system in type 2 diabetes. Genes Immun. 2011, 12, 239-250.
26. Feuerer, M., Herrero, L., Cipolletta, D., Naaz, A. et al., Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 2009, 15, 930-939.
27. Soderberg, C., Marmur, J., Eckes, K., Glaumann, H. et al., Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis. APMIS 2011, 119, 412-420.
28. Ammon, H. P., Wahl, M. A., Pharmacology of Curcuma longa. Planta Med. 1991, 57, 1-7.
29. Lao, C. D., Ruffin, M. T. T., Normolle, D., Heath, D. D. et al., Dose escalation of a curcuminoid formulation. BMC Complement Altern. Med. 2006, 6, 10.
30. Srinivasan, M., Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J. Med. Sci. 1972, 26, 269-270.
31. Weisberg, S. P., Leibel, R., Tortoriello, D. V., Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008, 149, 3549-3558.
32. Satoskar, R. R., Shah, S. J., Shenoy, S. G., Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int. J. Clin. Pharmacol. Ther. Toxicol. 1986, 24, 651-654.
33. Allegri, P., Mastromarino, A., Neri, P., Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. Clin. Ophthalmol. 2010, 4, 1201-1206.
34. Kurd, S. K., Smith, N., VanVoorhees, A., Troxel, A. B. et al., Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. J. Am. Acad. Dermatol. 2008, 58, 625-631.
35. Holt, P. R., Katz, S., Kirshoff, R., Curcumin therapy in inflammatory bowel disease: a pilot study. Dig. Dis. Sci. 2005, 50, 2191-2193.
36. Hanai, H., Iida, T., Takeuchi, K., Watanabe, F. et al., Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 2006, 4, 1502-1506.
37. Asawanonda, P., Klahan, S. O., Tetrahydrocurcuminoid cream plus targeted narrowband UVB phototherapy for vitiligo: a preliminary randomized controlled study. Photomedicine and laser surgery 2010, 28, 679-684.
38. Belcaro, G., Cesarone, M. R., Dugall, M., Pellegrini, L. et al., Product-evaluation registry of Meriva(R), a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med. 2010, 52, 55-62.
39. Durgaprasad, S., Pai, C. G., Vasanthkumar, Alvres, J. F., Namitha, S., A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J. Med. Res. 2005, 122, 315-318.
40. Koosirirat, C., Linpisarn, S., Changsom, D., Chawansuntati, K., Wipasa, J., Investigation of the anti-inflammatory effect of Curcuma longa in Helicobacter pylori-infected patients. Int. Immunopharmacol. 2010, 10, 815-818.
41. Li, Q., Verma, I. M., NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2002, 2, 725-734.
42. Dominiak, K., McKinney, J., Heilbrun, L. K., Sarkar, F. H., Critical need for clinical trials: an example of a pilot human intervention trial of a mixture of natural agents protecting lymphocytes against TNF-alpha induced activation of NF-kappaB. Pharm. Res. 2010, 27, 1061-1065.
43. Wickenberg, J., Ingemansson, S. L., Hlebowicz, J., Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects. Nutrition J. 2010, 9, 43, doi: 10.1186/1475-2891-9-43.
44. Chuengsamarn, S., Rattanamongkolgul, S., Luechapudiporn, R., Phisalaphong, C., Jirawatnotai, S., Curcumin extract for prevention of type 2 diabetes. Diabetes Care 2012, 35, 2121-2127.
45. Ramirez-Bosca, A., Soler, A., Carrion, M. A., Diaz-Alperi, J. et al., An hydroalcoholic extract of curcuma longa lowers the apo B/apo A ratio. Implications for atherogenesis prevention. Mech. Ageing Dev. 2000, 119, 41-47.
46. Na, L. X., Li, Y., Pan, H. Z., Zhou, X. L. et al., Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol. Nutr. Food Res. 2013, 57, 1569-1577.
47. Usharani, P., Mateen, A. A., Naidu, M. U., Raju, Y. S., Chandra, N., Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R. D. 2008, 9, 243-250.
48. Khajehdehi, P., Zanjaninejad, B., Aflaki, E., Nazarinia, M. et al., Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J. Ren. Nutr. 2012, 22, 50-57.
49. Khajehdehi, P., Pakfetrat, M., Javidnia, K., Azad, F. et al., Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand. J. Urol. Nephrol. 2011, 45, 365-370.
50. Anand, P., Kunnumakkara, A. B., Newman, R. A., Aggarwal, B. B., Bioavailability of curcumin: problems and promises. Mol. Pharm. 2007, 4, 807-818.
51. Shoba, G., Joy, D., Joseph, T., Majeed, M. et al., Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998, 64, 353-356.
52. Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M. et al., Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21, 2895-2900.
53. Ryu, E. K., Choe, Y. S., Lee, K. H., Choi, Y., Kim, B. T., Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J. Med. Chem. 2006, 49, 6111-6119.
54. Aggarwal, B. B., Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu. Rev. Nutr. 2010, 30, 173-199.
55. Shehzad, A., Ha, T., Subhan, F., Lee, Y. S., New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur. J. Nutr. 2011, 50, 151-161.
56. Cong, Y., Wang, L., Konrad, A., Schoeb, T., Elson, C. O., Curcumin induces the tolerogenic dendritic cell that promotes differentiation of intestine-protective regulatory T cells. Eur. J. Immunol. 2009, 39, 3134-3146.
57. Rogers, N. M., Kireta, S., Coates, P. T., Curcumin induces maturation-arrested dendritic cells that expand regulatory T cells in vitro and in vivo. Clin. Exp. Immunol. 2010, 162, 460-473.
58. Henao-Mejia, J., Elinav, E., Jin, C., Hao, L. et al., Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482, 179-185.
59. Sun, M., Su, X., Ding, B., He, X. et al., Advances in nanotechnology-based delivery systems for curcumin. Nanomedicine 2012, 7, 1085-1100.
60. Mohanty, C., Das, M., Sahoo, S. K., Emerging role of nanocarriers to increase the solubility and bioavailability of curcumin. Expert Opin. Drug Deliv. 2012, 9, 1347-1364.
61. Yekollu, S. K., Thomas, R., O'Sullivan, B., Targeting curcusomes to inflammatory dendritic cells inhibits nf-{kappa}b and improves insulin resistance in obese mice. Diabetes 2011, 60, 2928-2938.
62. Belcaro, G., Cesarone, M. R., Dugall, M., Pellegrini, L. et al., Efficacy and safety of Meriva(R), a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern. Med. Rev. 2010, 15, 337-344.
63. Appendino, G., Belcaro, G., Cornelli, U., Luzzi, R. et al., Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy. A pilot study. Panminerva Med. 2011, 53, 43-49.